PLP1 and Pelizeaus-Merzbacher spectrum disorder: An interventional trial to assess the safety, pharmacokinetics, and pharmacodynamics of IT ION356, an ASO targeting PLP1, is currently enrolling male PMD patients between two and 17 years old with a PLP1 duplication (NCT06150716).